Lead Placement Agent on Perspective Therapeutics' $87.4MM Private Placement

Perspective Therapeutics, Inc. (“Perspective”) (NYSEAM: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced that it has entered into an investment agreement with a select group of institutional accredited investors to sell 92,009,981 shares of its common stock at a price of $0.95 per share, representing the closing price per share of Perspective’s common stock on the NYSE American as of March 1, 2024. Gross proceeds were approximately $87.4 million before deducting placement agent fees and other offering expenses.

Perspective recently announced an exclusive license agreement with Stony Brook University for the rights to its Cuburbit[7]uril-admantane (CB7-Adma) pre-targeting platform and was awarded $2.4 million from the National Institutes of Health (NIH) National Cancer Institute in support of CB7-Adma. In early January, Perspective made two strategic announcements: a co-development option arrangement with Lantheus Holdings for Perspective’s 212PbVMT-α-NET program which included a $28.0 million upfront payment, and an exclusive license agreement with Mayo Clinic for the rights to the PSMA Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate. Perspective also recently began recruitment for the second dosing cohorts in clinical studies for both of its lead programs: 212PbVMT-α-NET and 212PbVMT0.